Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LFMD Stock Forecast 2026-2027
$4.53
Current Price
$216.60M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LFMD Price Targets
+231.1%
To High Target of $15.00
+120.8%
To Median Target of $10.00
+76.6%
To Low Target of $8.00
LFMD Price Momentum
+18.3%
1 Week Change
+16.2%
1 Month Change
-19.8%
1 Year Change
+32.8%
Year-to-Date Change
-71.4%
From 52W High of $15.84
+77.0%
From 52W Low of $2.56
📊 TOP ANALYST CALLS
Did LFMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LifeMD is one of their latest high-conviction picks.
Latest LFMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, LFMD has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $15.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.53, the median forecast implies a 120.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sarah James at Cantor Fitzgerald, projecting a 231.1% upside. Conversely, the most conservative target is provided by Steven Valiquette at Mizuho, suggesting a 76.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFMD Analyst Ratings
8
Buy
0
Hold
0
Sell
LFMD Price Target Range
Low
$8.00
Average
$10.00
High
$15.00
Current: $4.53
Latest LFMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 16, 2026 | Mizuho | Steven Valiquette | Outperform | Upgrade | $8.00 |
| Mar 12, 2026 | Freedom Broker | Ilya Zubkov | Buy | Maintains | $10.00 |
| Mar 12, 2026 | Freedom Capital Markets | Ilya Zubkov | Buy | Maintains | $10.00 |
| Mar 11, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $10.00 |
| Mar 10, 2026 | BTIG | David Larsen | Buy | Reiterates | $10.00 |
| Nov 24, 2025 | Freedom Broker | Buy | Maintains | $N/A | |
| Nov 19, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $8.00 |
| Nov 19, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $9.00 |
| Nov 19, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $6.00 |
| Nov 18, 2025 | BTIG | David Larsen | Buy | Maintains | $10.00 |
| Nov 18, 2025 | B. Riley Securities | William Woods | Buy | Maintains | $10.00 |
| Nov 18, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $8.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $13.00 |
| Aug 6, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $12.00 |
| Aug 6, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $14.00 |
| Jul 14, 2025 | Keybanc | Aleksey Yefremov | Overweight | Maintains | $14.00 |
| Jul 10, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $18.00 |
| Apr 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $14.00 |
| Mar 11, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
LifeMD Inc. (LFMD) Competitors
The following stocks are similar to LifeMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LifeMD Inc. (LFMD) Financial Data
Valuation Metrics
Market Cap
$216.60M
Enterprise Value
$165.75M
P/E Ratio
N/A
PEG Ratio
11.4x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
-27.1%
Gross Margin
+40.2%
Operating Margin
-2.3%
Net Margin
+7.4%
EPS Growth
-89.0%
Financial Health
Cash/Price Ratio
+16.9%
Current Ratio
1.2x
Debt/Equity
27.3x
ROE
-131.2%
ROA
-6.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
LifeMD Inc. (LFMD) Business Model
About LifeMD Inc.
What They Do
Provides telehealth and pharmacy services.
Business Model
The company operates a direct-to-patient telehealth platform that generates revenue by connecting consumers with healthcare professionals for virtual consultations and offering pharmacy solutions, including digital prescriptions and medication fulfillment. It also monetizes through specialized brands targeted at men's health and weight management, as well as collaborations with pharmaceutical partners for medications.
Additional Information
LifeMD Inc. has positioned itself as a pure-play virtual care and pharmacy provider, especially after divesting its software segment. The company emphasizes cost-effective healthcare access and leverages its expertise in medicine and technology to enhance patient experiences. It is headquartered in New York, NY.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
347
CEO
Mr. Justin Schreiber
Country
United States
IPO Year
2021
Website
lifemd.comLifeMD Inc. (LFMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Apr 14, 2026
By Debanjana Dey
Analyst Blog
Latest News
Quick Summary
LifeMD has expanded its weight management program by adding Foundayo, providing eligible patients with an oral alternative to injectable GLP-1 therapies via LillyDirect®.
Why It Matters
LifeMD's expansion of its weight management program with Foundayo could enhance revenue streams, attract more patients, and strengthen its competitive position in the growing obesity treatment market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LifeMD expands its partnership with Novo Nordisk, offering up to $1,200 in annual savings for patients on branded GLP-1 therapy.
Why It Matters
The collaboration between LifeMD and Novo Nordisk could enhance market competitiveness and drive revenue growth, positively impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LifeMD, Inc. (Nasdaq: LFMD) announced a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP).
Why It Matters
LifeMD's announcement of a cash dividend signals financial stability and commitment to returning value to shareholders, potentially attracting more investors and boosting stock prices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
1 month ago
Quick Summary
LifeMD, Inc. (Nasdaq: LFMD) appointed Atul Kavthekar as CFO, effective March 16, 2026, alongside other leadership changes to facilitate growth.
Why It Matters
Leadership changes and a new CFO can signal strategic shifts and growth potential for LifeMD, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LifeMD, Inc. (LFMD) reported a quarterly loss of $0.04 per share, worse than the expected loss of $0.01, and a decline from a loss of $0.02 per share a year earlier.
Why It Matters
LifeMD's larger-than-expected quarterly loss signals potential operational challenges, which may impact investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
LifeMD (LFMD) is rated Buy, trading at 0.796x TTM sales. The divestment of WorkSimpli refocused it on telehealth and pharmacy, with growth potential from the new Wegovy pill.
Why It Matters
LifeMD's low trading multiple suggests undervaluation, while its refocused strategy and new Wegovy pill launch position it for potential growth, making it an attractive investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About LFMD Stock
What is LifeMD Inc.'s (LFMD) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, LifeMD Inc. (LFMD) has a median price target of $10.00. The highest price target is $15.00 and the lowest is $8.00.
Is LFMD stock a good investment in 2026?
According to current analyst ratings, LFMD has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LFMD stock?
Wall Street analysts predict LFMD stock could reach $10.00 in the next 12 months. This represents a 120.8% increase from the current price of $4.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LifeMD Inc.'s business model?
The company operates a direct-to-patient telehealth platform that generates revenue by connecting consumers with healthcare professionals for virtual consultations and offering pharmacy solutions, including digital prescriptions and medication fulfillment. It also monetizes through specialized brands targeted at men's health and weight management, as well as collaborations with pharmaceutical partners for medications.
What is the highest forecasted price for LFMD LifeMD Inc.?
The highest price target for LFMD is $15.00 from Sarah James at Cantor Fitzgerald, which represents a 231.1% increase from the current price of $4.53.
What is the lowest forecasted price for LFMD LifeMD Inc.?
The lowest price target for LFMD is $8.00 from Steven Valiquette at Mizuho, which represents a 76.6% increase from the current price of $4.53.
What is the overall LFMD consensus from analysts for LifeMD Inc.?
The overall analyst consensus for LFMD is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are LFMD stock price projections?
Stock price projections, including those for LifeMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:13 AM UTC